The needs for HIV treatment and care of children, adolescents, pregnant women and older people in low-income and middle-income countries

AIDS

Volumn 26, Issue SUPPL.2, 2012, Pages

  Kenny, Julia ^a,b   Mulenga, Veronica ^c   Hoskins, Susan ^a   Scholten, Francien ^d   Gibb, Diana M ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

^d UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; DAPSONE; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; S GSK 1265744; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADOLESCENCE; ALLERGIC REACTION; ANEMIA; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CHILD HEALTH CARE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG TOLERABILITY; GERIATRIC PATIENT; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PATIENT REFERRAL; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; VIRUS EXAMINATION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CHILD; CHILD HEALTH SERVICES; DEVELOPING COUNTRIES; FEMALE; HEALTH SERVICES FOR THE AGED; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84872851721     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835bddfc     Document Type: Article

References (122)

1. WHO/UNAIDS/UNICEF. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. 2010. http://www.who.int/hiv/pub/tuapr- 2009-en.pdf. [Accessed 22 November 2012]
2. UN. UN Inter-agency Group for Child Mortality Estimation. Levels and Trends in Child Mortality. 2010. http://www.childinfo.org/files/Child-Mortality- Report-2012.pdf. [Accessed 22 November 2012]
3. UNAIDS. Report on the global AIDS epidemic. 2010. http://www.unaids.org/ globalreport/global-report.htm. [Accessed 22 November 2012]
4. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243. (Pubitemid 39311344)
5. UNAIDS. UNAIDS Treatment 2.0. 2011. http://data.unaids.org/pub/Outlook/ 2010/20100713-outlook-treatment2-0-en.pdf. [Accessed 22 November 2012]
6. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011; 378: 282-284.
7. WHO. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, version 2. 2010. http://whqlibdoc.who.int/ publications/2009/9789241598934-eng.pdf. [Accessed 22 November 2012]
8. UNAIDS. Countdown to Zero. 2011. http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/20110609-JC2137-Global-Plan- Elimination-HIVChildren-en.pdf. [Accessed 22 November 2012]
9. Munderi P, Grosskurth H, Droti B, Ross DA. What are the essential components of HIV treatment and care services in low and middle-income countries: an overview by settings and levels of the health system? AIDS 2012; 26 (Suppl 2):S97-S103.
10. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
11. Foster C, Judd A, Tookey P, Tudor-Williams G, Dunn D, Shingadia D, et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS 2009; 23:159-166.
12. Ferrand RA, Luethy R, Bwakura F, Mujuru H, Miller RF, Corbett EL. HIV infection presenting in older children and adolescents: a case series from Harare, Zimbabwe. Clin Infect Dis 2007; 44:874-878. (Pubitemid 46365317)
13. Foster C, Fidler S. Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection. Expert Rev Anti Infect Ther 2010; 8:1403-1416.
14. Funck-Brentano I, Dalban C, Veber F, Quartier P, Hefez S, Costagliola D, et al. Evaluation of a peer support group therapy for HIV-infected adolescents. AIDS 2005; 19:1501- 1508. (Pubitemid 41400696)
15. Braitstein P, Songok J, Vreeman RC, Wools-Kaloustian KK, Koskei P, Walusuna L, et al. 'Wamepotea' (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr 2011; 57:e40-e46.
16. Fetzer BC, Hosseinipour MC, Kamthuzi P, Hyde L, Bramson B, Jobarteh K, et al. Predictors for mortality and loss to follow-up among children receiving antiretroviral therapy in Lilongwe, Malawi. Trop Med Int Health 2009; 14:862-869.
17. Fenner L, Brinkhof MWG, Keiser O, Weigel R, Cornell M, Moultrie H, et al. Early mortality and loss to follow-up in HIVinfected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr 2010; 54:524-532.
18. WHO. WHO recommendations on the diagnosis of HIV infection in infants and children. 2010. http://www.who.int/hiv/pub/paediatric/diagnosis/en/index.html. [Accessed 22 November 2012]
19. Patton JC, Coovadia AH, Meyers TM, Sherman GG. Evaluation of the ultrasensitive human immunodeficiency virus type 1 (HIV-1) p24 antigen assay performed on dried blood spots for diagnosis of HIV-1 infection in infants. Clin Vaccine Immunol 2008; 15:388-391. (Pubitemid 352025526)
20. Stevens WS, Noble L, Berrie L, Sarang S, Scott LE. Ultra-highthroughput, automated nucleic acid detection of human immunodeficiency virus (HIV) for infant infection diagnosis using the Gen-Probe Aptima HIV-1 screening assay. J Clin Microbiol 2009; 47:2465-2469.
21. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr 2005; 38:615-617. (Pubitemid 40524486)
22. Cachafeiro A, Sherman GG, Sohn AH, Beck-Sague C, Fiscus SA. Diagnosis of human immunodeficiency virus type 1 infection in infants by use of dried blood spots and an ultrasensitive p24 antigen assay. J Clin Microbiol 2009; 47:459-462.
23. Mehta N, Trzmielina S, Nonyane BAS, Eliot MN, Lin R, Foulkes AS, et al. Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR. PLoS One 2009; 4:e5819.
24. Mukund BKC, Murray PJ. Cell phone short messaging service (SMS) for HIV/AIDS in South Africa: a literature review. Stud Health Technol Inform 2010; 160 (Pt 1):530-534.
25. Seidenberg P, Nicholson S, Schaefer M, Semrau K, Bweupe M, Masese N, et al. Early infant diagnosis of HIV infection in Zambia through mobile phone texting of blood test results. Bull World Health Organ 2012; 90:348-356.
26. Inwani I, Mbori-Ngacha D, Nduati R, Obimbo E, Wamalwa D, John-Stewart G, et al. Performance of clinical algorithms for HIV-1 diagnosis and antiretroviral initiation among HIV-1- exposed children aged less than 18 months in Kenya. J Acquir Immune Defic Syndr 2009; 50:492-498.
27. Jaspan H, Myer L, Madhi S, Violari A, Gibb D, Stevens W, et al. Utility of clinical parameters to identify HIV infection in infants below ten weeks of age in South Africa: a prospective cohort study. BMC Pediatr 2011; 11:104.
28. Peltier CA, Omes C, Ndimubanzi PC, Ndayisaba GF, Stulac S, Arendt V, et al. Validation of 2006WHOprediction scores for true HIV infection in children less than 18 months with a positive serological HIV test. PLoS One 2009; 4:e5312.
29. Stewart R, Bunn J, Vokhiwa M, Umar E, Kauye F, Tomenson B, et al. A prospective study of psychological distress among mothers of children admitted to a nutritional rehabilitation unit in Malawi. Child Care Health Dev 2011; 37:55-63.
30. Mine M, Ntsipe T, Nkoane T, Moyo S, Gaolathe T. Evaluation of determine and UniGold rapid test kits for serologic screening of HIV-exposed but uninfected infants under 18 months of age in a modified testing algorithm in Botswana. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011; Hynes Convention Center, Boston, MA, USA.
31. WHO. Antiretroviral Therapy for HIV infection in infants and children: towards universal access. 2010. http://whqlibdoc.-who.int/publications/2010/ 9789241599801-eng.pdf. [Accessed 23 November 2012]
32. Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996- 2008: treatment response and duration of first line regimens. AIDS 2011;25:2279-2287.
33. Dunn DT, Gibb DM, Duong T, Babiker AG, Aboulker JP, Bulterys M, et al. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20:1289-1294.
34. UNICEF/UNAIDS. Children and AIDS fourth stocktaking report. 2009. http://www.unicef.org/publications/files/Children-and-AIDS-Fourth-Stocktaking- Report-EN-110609.pdf. [Accessed 22 November 2012]
35. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double- blind randomised placebo-controlled trial. Lancet 2004; 364:1865-1871. (Pubitemid 39536090)
36. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353:1463-1468. (Pubitemid 29204363)
37. Mwaungulu FBD, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Org 2004; 82:354-363. (Pubitemid 38715072)
38. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428-1434. (Pubitemid 39370718)
39. Zachariah R, Spielmann MPL, Chinji C, Gomani P, Arendt V, Hargreaves NJ, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003; 17:1053.
40. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-1475. (Pubitemid 29204364)
41. Walter J, Mwiya M, Scott N, Kasonde P, Sinkala M, Kankasa C, et al. Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts. J Infect Dis 2006; 194:1510-1518. (Pubitemid 44851892)
42. WHO. WHO Cotrimoxazole guidelines. 2011. http://www.who.int/hiv/pub/ guidelines/WHO%20CTX.pdf. [Accessed 23 November 2012]
43. Ryan M, Griffin S, Chitah B, Walker AS, Mulenga V, Kalolo D, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS 2008; 22:749- 757. (Pubitemid 351450644)
44. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375:1278-1286.
45. National AIDS Commission MoHaP. Treatment of AIDS: guidelines for the use of antiretroviral therapy in Malawi. 1st ed. 2003.
46. Ellis JC, L'homme RF, Ewings FM, Mulenga V, Bell F, Chileshe R, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12: 253-260. (Pubitemid 46569910)
47. O'Brien DP, Sauvageot D, Zachariah R, Humblet P. In resource- limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006; 20:1955-1960. (Pubitemid 44427613)
48. Nahirya-Ntege P, Bakura Dangarembizi M, Cook A, Akeera- Kitaka S, Keishanyu R, Mudzingwa S, et al. Tablets are more acceptable and give fewer problems than syrups among young HIV-infected children in resource limited settings in the ARROW trial. In: Proceedings of the XVIII International AIDS Conference; 18-23 July 2010; Vienna, Austria; abstract TUPDB206.
49. The PENPACT-1 (PENTA 9 /PACTG 390) Study Team. First-line antiretroviral therapy initiation with a protease inhibitor versus nonnucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIVinfected children: an open randomised controlled phase 2/3 trial. Lancet Infect Dis 2011; 11:273-283.
50. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510-1520.
51. Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, Mofenson L, et al. NVP- vs LPV/r-based ART among HIVR infants in resource-limited settings: the IMPAACT P1060 Trial. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011; Hynes Convention Center, Boston, MA, USA; paper 129LB.
52. Moorthy A, Kuhn L, Coovadia A, Meyers T, Strehlau R, Sherman G, et al. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis 2011; 52:514-521.
53. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010; 304:1082-1090.
54. Lallemant M, Chang S, Cohen R, Pecoul B. Pediatric HIV: a neglected disease? N Engl J Med 2011; 365:581-583.
55. Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, Walker AS, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22:557-565. (Pubitemid 351640588)
56. William J Clinton Foundation. UNITAID and the Clinton HIV/ AIDS Initiative Announce New Price Reductions for Key AIDS Medicines. 2009.
57. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007; 101:793-798. (Pubitemid 46947861)
58. Nahirya-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P, et al. Low Incidence of Abacavir Hypersensitivity Reaction Among African Children Initiating Antiretroviral Therapy. Pediatr Infect Dis J 2011; 30:535- 537.
59. Were TP. Prevalence and factors associated with lipodystrophy among children on HAART at the paediatric infectious diseases clinic, Mulago Hospital. In: Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections; 16- 19 February 2009; Moscon Center West, San Francisco, CA, USA; paper 869.
60. Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FAI, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006; 332:1183.
61. van Rossum A, Fraaij PLA, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002; 2:93-102. (Pubitemid 36114143)
62. Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011; 377:1580- 1587.
63. Cotton M, Violari A, Gibb D, Otwombe K, Josipovic D, Panchia R, et al. Early ART followed by interruption is safe and is associated with better outcomes than deferred ART in HIVR infants: final results from the 6-year randomized CHER trial, South Africa. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Washington State Convention Center; Seattle, WA.
64. Wamalwa D, Benki-Nugent S, Langat A, Tapia K, Ngugi E, Moraa H, et al. Treatment interruption in infants following 24 months of empiric ART: Kenya. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012;Washington StateConvention Center; Seattle, WA.
65. Valerius NH. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010; 24:231- 241.
66. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
67. Violari A, Cotton M, Otwombe K, Hunt G, Kalimashe M, Panchia R, et al. Does Early Limited ART in infants affect virologic and resistance outcomes? Data from the 6 year CHER trial CHER (Children with HIV Early antiRetroviral). Eleventh International Congress on Drug Therapy in HIV Infection; 11-15 November 2012. Glasgow, UK. 2012 Nov 11; 2012.
68. Bunupuradah T, Duong T, Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, et al. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions in the PENTA 11 Study. AIDS 2012; in press.
69. Steinmann GG. Changes in the human thymus during aging. Curr Topics Pathol 1986; 75:43-88.
70. De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1 infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis 2002; 186:312-320. (Pubitemid 34816314)
71. Cohen C, Colson A, Pierone G, Dejesus E, Kinder F, Elion R, et al. The FOTO study: the 48 week extension to assess durability of the strategy of taking efavirenz, tenofovir and emtricitabine Five days On, Two days Off (FOTO) each week in virologically suppressed patients. In: Proceedings of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 19-22 July 2009; Cape Town, South Africa.
72. Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One 2010; 5:e10307.
73. UNAIDS. Report on the global AIDS epidemic. Geneva: UNAIDS; 2009. http://www.unaids.org/globalreport/global-report.htm. [Accessed 23 November 2012]
74. Butler AM, Williams PL, Howland LC, Storm D, Hutton N, Seage GR. Impact of disclosure of HIV infection on healthrelated quality of life among children and adolescents with HIV infection. Pediatrics 2009; 123:935-943.
75. Vaz LME, Maman S, Eng E, Barbarin OA, Tshikandu T, Behets F. Patterns of disclosure of HIV status to infected children in a sub-Saharan African setting. J Dev Behav Pediatr 2011; 32:307.
76. Vaz LME, Eng E, Maman S, Tshikandu T, Behets F. Telling children they have HIV: lessons learned from findings of a qualitative study in sub-Saharan Africa. AIDS Patient Care STDS 2010; 24:247-256.
77. Ferrand RA, Bandason T, Musvaire P, Larke N, Nathoo K, Mujuru H, et al. Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic - a prospective survey. PLoS Med 2010; 7:e1000178.
78. Bakeera-Kitaka S, McKellar M, Snider C, Kekitiinwa A, Piloya T, Musoke P, et al. Antiretroviral therapy for HIV- 1 infected adolescents in Uganda: assessing the impact on growth and sexual maturation. J Pediatr Infect Dis 2008; 3:97-104. (Pubitemid 351850475)
79. Kekitiinwa A, Lee KJ, Walker AS, Maganda A, Doerholt K, Kitaka SB, et al. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr 2008; 49:384-392.
80. Birungi H, Mugisha JF, Obare F, Nyombi JK. Sexual behavior and desires among adolescents perinatally infected with human immunodeficiency virus in Uganda: implications for programming. J Adolesc Health 2009; 44:184-187.
81. UNICEF. Adolescence: an age of opportunity. 2011. http://www.unicef.org/ sowc2011/. [Accessed 23 November 2012]
82. Homsy J, Bunnell R, Moore D, King R, Malamba S, Nakityo R, et al. Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study. PLoS One 2009; 4:e4149.
83. WHO/UNAIDS/UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. 2010. http://www.who.int/hiv/pub/tuapr- 2009-en.pdf. [Accessed 23 November 2012]
84. Homsy J, Kalamya JN, Obonyo J, Ojwang J, Mugumya R, Opio C, et al. Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital. J Acquir Immune Defic Syndr 2006; 42:149-154. (Pubitemid 43884708)
85. Bakari JP, McKenna S, Myrick A, Mwinga K, Bhat GJ, Allen S. Rapid voluntary testing and counseling for HIV: acceptability and feasibility in Zambian antenatal care clinics. Ann N Y Acad Sci 2000; 918:64-76.
86. Evidence for Action. Missed opportunities to enrol women testing HIV-positive in antenatal and delivery services into long-term HIV care and treatment. Evidence for Action Policy Briefing, Issue No. 9, 1 May 2011.
87. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021. (Pubitemid 350018545)
88. Farr SL, Nelson JAE, Ng'ombe TJ, Kourtis AP, Chasela C, Johnson JA, et al. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr 2010; 54:515-523.
89. WHO. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2009.
90. McCarthy E, Ipuge Y, Silaa R, Ramadhani A, Njau P, Michaelis A, et al. Cost-effectiveness of options A and B of the 2010 WHO PMTCT antiretroviral guidelines in Tanzania. In: Proceedings of the IAS Conference on PMTCT and pediatrics impact and cost model; Rome, 17 July 2011.
91. Manzi M, Zachariah R, Teck R, Buhendwa L, Kazima J, Bakali E, et al. High acceptability of voluntary counselling and HIV testing but unacceptable loss to follow up in a prevention of mother to child HIV transmission programme in rural Malawi: scaling up requires a different way of acting. Trop Med Int Health 2005; 10:1242-1250. (Pubitemid 41789677)
92. Black RE, Allen LH, Bhutta ZA, Caulfield LE, De Onis M, Ezzati M, et al. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008; 371:243-260.
93. Miotti PG, Taha TET, Kumwenda NI, Broadhead R, Mtimavalye LAR, Van der Hoeven L, et al. HIV transmission through breastfeeding. JAMA 1999; 282:744-749.
94. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340:585-588.
95. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1. JAMA 2000; 283:1167-1174. (Pubitemid 30126605)
96. Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107- 1116. (Pubitemid 46483637)
97. Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 2005; 19:699.
98. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No.: CD003510. DOI: 10.1002/ 14651858.CD003510.pub3.
99. Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011; 57:290-296.
100. Negin J, Cumming RG. HIV infection in older adults in sub- Saharan Africa: extrapolating prevalence from existing data. Bull World Health Org 2010; 88:847-853.
101. Shisana O, Human Sciences RC, Centre for AIDS Development RaE. South African national HIV prevalence, incidence, behaviour and communication survey, 2008: a turning tide among teenagers? Cape Town: HSRC Press; 2009.
102. Smith RD, Delpech VC, Brown AE, Rice BD. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010; 24:2109-2115.
103. Lazarus JV, Nielsen KK. HIV and people over 50 years old in Europe. HIV Med 2010; 11:479-481.
104. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Mcfarland Horne F, et al. Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47:542-553.
105. Schmid GP, Williams BG, Garcia-Calleja JM, Miller C, Segar E, Southworth M, et al. The unexplored story of HIV and ageing. Bull World Health Org 2009; 87:162-162A.
106. Orlando G, Meraviglia P, Cordier L, Meroni L, Landonio S, Giorgi R, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006; 7:549-557. (Pubitemid 44742356)
107. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357: 762-774. (Pubitemid 47295643)
108. Shisana O, Simbayi L. South African national HIV prevalence, HIV incidence, behaviour and communication survey, 2005. Human Sciences Research Council; 2008.
109. Zingmond DS, Kilbourne AM, Justice AC, Wenger NS, Rodriguez-Barradas M, Rabeneck L, et al. Differences in symptom expression in older HIV-positive patients: the Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr 2003; 33:S84- S92. (Pubitemid 36801606)
110. Shah S, Mildvan D. HIV and aging. Curr Infect Dis Rep 2006; 8:241-247.
111. Bianco JA, Heckman TG, Sutton M, Watakakosol R, Lovejoy T. Predicting adherence to antiretroviral therapy in HIV-infected older adults: the moderating role of gender. AIDS Behav 2011;15:1-10.
112. Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez- Barradas M, et al. Do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45:1593- 1601. (Pubitemid 351411845)
113. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El- Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
114. Oursler KK, Sorkin JD, Smith BA, Katzel LI. Reduced aerobic capacity and physical functioning in older HIV-infected men. AIDS Res Hum Retroviruses 2006; 22:1113-1121. (Pubitemid 44904262)
115. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007; 62:1279-1286. (Pubitemid 350287617)
116. Scholten F, Mugisha J, Seely J, Kinyanda E, Nakubukwa S, Kowal P, et al. Health and functional status among older people with HIV/AIDS in Uganda. BMC Public Health 2011; 11:886.
117. Nyirenda M, Chatterji S, Falkingham J, Mutevedzi P, Hosegood V, Evandrou M, et al. An investigation of factors associated with the health and well-being of HIV-infected or HIVaffected older people in rural South Africa. BMC Public Health 2012; 12:259.
118. Catz SL, Heckman TG, Kochman A, DiMarco M. Rates and correlates of HIV treatment adherence among late middleaged and older adults living with HIV disease. Psychol Health Med 2001; 6:47-58. (Pubitemid 32154904)
119. Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, et al. Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting. AIDS Care 2010; 22:381-389.
120. Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou TA, Rourke SB, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/ AIDS. Cochrane Database Syst Rev 2006:CD001442.
121. International Center for Research on Women (ICRW). Finding solutions to strengthen HIV AIDS programs. Washington D.C. 2006. http://www.ircw.org/ publications/hivaids-stigma-finding-solutions-strengthen-hivaids-programs.
122. Hoskins S, Weller I, Jahn A, Kaleebu P, Malyuta R, Kirungi W, et al. An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries. AIDS 2010; 24:2603.